Voyager Therapeutics, Inc. (NASDAQ:VYGR)‘s stock had its “buy” rating restated by investment analysts at Cowen and Company in a research note issued to investors on Tuesday.

The analysts wrote, “VYGR had a 6/30 cash balance of $141MM, sufficient to fund operations into 2019.””

Several other research firms have also recently weighed in on VYGR. Stifel Nicolaus initiated coverage on Voyager Therapeutics in a report on Friday, July 28th. They issued a “buy” rating and a $20.00 price objective for the company. BidaskClub upgraded Voyager Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, July 13th. TheStreet cut Voyager Therapeutics from a “c-” rating to a “d+” rating in a research note on Friday, April 21st. Zacks Investment Research cut Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. Finally, Wedbush restated an “outperform” rating and issued a $36.00 target price on shares of Voyager Therapeutics in a research note on Wednesday, May 10th. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $25.33.

Shares of Voyager Therapeutics (NASDAQ:VYGR) traded up 4.90% during trading on Tuesday, reaching $8.78. The company’s stock had a trading volume of 198,453 shares. Voyager Therapeutics has a 52-week low of $8.10 and a 52-week high of $18.25. The stock’s 50 day moving average price is $9.40 and its 200-day moving average price is $10.71. The stock’s market cap is $235.76 million.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Tuesday, May 9th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.54) by $0.11. Voyager Therapeutics had a negative return on equity of 35.25% and a negative net margin of 457.45%. The business had revenue of $1.46 million during the quarter, compared to analysts’ expectations of $3.70 million. Equities analysts anticipate that Voyager Therapeutics will post ($2.54) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/08/voyager-therapeutics-inc-nasdaqvygr-rating-reiterated-by-cowen-and-company.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in VYGR. Russell Investments Group Ltd. purchased a new position in Voyager Therapeutics during the fourth quarter worth approximately $194,000. Fiduciary Trust Co. boosted its position in Voyager Therapeutics by 19.1% in the first quarter. Fiduciary Trust Co. now owns 108,561 shares of the company’s stock worth $1,437,000 after buying an additional 17,386 shares during the last quarter. Wellington Management Group LLP boosted its position in Voyager Therapeutics by 17.4% in the first quarter. Wellington Management Group LLP now owns 131,312 shares of the company’s stock worth $1,739,000 after buying an additional 19,450 shares during the last quarter. Teachers Advisors LLC boosted its position in Voyager Therapeutics by 9.8% in the fourth quarter. Teachers Advisors LLC now owns 20,604 shares of the company’s stock worth $262,000 after buying an additional 1,847 shares during the last quarter. Finally, Hershey Trust Co. boosted its position in Voyager Therapeutics by 163.0% in the second quarter. Hershey Trust Co. now owns 14,394 shares of the company’s stock worth $129,000 after buying an additional 8,921 shares during the last quarter. Institutional investors own 41.34% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.